The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 1-2 , 22 March 2004

Introduction

  • Peter Libby, MD

      Affiliations

    • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Peter Libby, MD, Donald W. Reynolds Cardiovascular Clinical Research Center, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, Massachusetts 02115.

References 

  1. Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36–69
  2. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333–1445
  3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study (4S)). Lancet. 1994;344:1383–1389
  5. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study (identification of high-risk groups and comparison with other cardiovascular intervention trials). Lancet. 1996;348:1339–1342
  6. Goldberg RB, Mellies MJ, Sacks FM, et al.  CARE Investigators  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol level (subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial). Circulation. 1998;98:2513–2519
  7. Gotto AM, Whitney E, Stein EA, et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  8. Tonkin AM, Colquhoun D, Emberson J, et al.  LIPID Study Group  Effects of pravastatin in 3260 patients with unstable angina (results from the LIPID study). Lancet. 2000;335:1871–1875
  9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (a randomised placebo-controlled trial). Lancet. 2002;360:7–22
  10. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease (a meta-analysis of randomized clinical trials). JAMA. 1999;282:2340–2346
  11. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  12. Pearson TA, Mensah GA, Alexander RW, et al.  Markers of inflammation and cardiovascular disease. Application to clinical and public health practice (a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association). Circulation. 2003;107:499–511
  13. Kastelein JJ, Wiegman A, de Groot E. Surrogate markers of atherosclerosis (impact of statins). Atherosclerosis. 2003;4(suppl):31–36

PII: S0002-9343(04)00070-1

doi: 10.1016/j.amjmed.2004.02.004

The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 1-2 , 22 March 2004

Article Tools